Seroprevalence of Dengue Infection Using IgG Capture ELISA in India, 2017–2018

Kumar, Muthusamy Santhosh; Pattabi, Kamaraj; Khan, Siraj Ahmed; Allam, Ramesh Reddy; Barde, Pradip V; Dwibedi, Bhagirathi; Kanungo, Suman; Mohan, Uday; Mohanty, Suman Sundar; Roy, Subarna; Sagar, Vivek; Savargaonkar, Deepali; Tandale, Babasaheb V; Topno, Roshan Kamal; Kumar, C. P. Girish; Sabarinathan, R.; Kumar, Velusamy Saravana; Karunakaran, T.; Jose, Annamma; Sadhukhan, Provash Chandra; Toteja, G S; Murhekar, Manoj

doi:10.4269/ajtmh.21-0386

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DENV seroprevalence in Southern Malaysia was reported to be 86.6% based on Panbio IgG indirect ELISA with a positive rate of 11.2% based on Panbio IgG-capture ELISA [ 23 ]. Similarly, DENV seroprevalence was reported to be 85–90% and 81.4% based on Panbio indirect IgG ELISA in Columbia and India, respectively, with positive rates of 16% and 8.1% based on Panbio IgG-capture ELISA [ 24 – 26 ]. Another study reported DENV seroprevalence of 8.9% based on Panbio indirect IgG ELISA with a 1.4% positive rate based on Panbio IgG-capture ELISA in Madeira Island [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…of samples Source of study (No.) Confirmation Country and year pDENV 42 seroprevalence study [ 20 ] Neutralization test b Taiwan, 2015-16 [ 33 ] Neutralization test b Brazil, 2016-17 [ 37 ] DENV study [ 7 ] RT-PCR Taiwan, 2001-9 [ 35 ] DENV study [ 11 ] RT-PCR Hawaii, 2015 [ 35 ] sDENV 88 seroprevalence study [ 39 ] Neutralization test b Taiwan, 2015-16 [ 33 ] ZIKV study [ 21 ] Neutralization test b Brazil, 2016-17 [ 37 ] DENV study [ 26 ] RT-PCR Taiwan, 2001-9 [ 35 ] DENV study [ 2 ] RT-PCR Hawaii, 2015 [ 35 ] DENV-naïve 49 seroprevalence study (49) Neutralization test b or multiple ELISAs …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study

Tsai

Lin

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background Dengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. Currently Dengvaxia, the first dengue vaccine licensed in 20 countries, was recommended for DENV seropositive individuals aged 9–45 years. Studying dengue seroprevalence can improve our understanding of the epidemiology and transmission dynamics of DENV, and facilitate future intervention strategies and assessment of vaccine efficacy. Several DENV envelope protein-based serological tests including IgG and IgG-capture enzyme-linked immunosorbent assays (ELISAs) have been employed in seroprevalence studies. Previously DENV IgG-capture ELISA was reported to distinguish primary and secondary DENV infections during early convalescence, however, its performance over time and in seroprevalence study remains understudied. Methods In this study, we used well-documented neutralization test- or reverse-transcription-polymerase-chain reaction-confirmed serum/plasma samples including DENV-naïve, primary and secondary DENV, primary West Nile virus, primary Zika virus, and Zika with previous DENV infection panels to compare the performance of three ELISAs. Results The sensitivity of the InBios IgG ELISA was higher than that of InBios IgG-capture and SD IgG-capture ELISAs. The sensitivity of IgG-capture ELISAs was higher for secondary than primary DENV infection panel. Within the secondary DENV infection panel, the sensitivity of InBios IgG-capture ELISA decreased from 77.8% at < 6 months to 41.7% at 1–1.5 years, 28.6% at 2–15 years and 0% at > 20 years (p < 0.001, Cochran-Armitage test for trend), whereas that of IgG ELISA remains 100%. A similar trend was observed for SD IgG-capture ELISA. Conclusions Our findings demonstrate higher sensitivity of DENV IgG ELISA than IgG-capture ELISA in seroprevalence study and interpretation of DENV IgG-capture ELISA should take sampling time and primary or secondary DENV infection into consideration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study

Tsai

Lin

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…In patients with either dengue NS1 and/or IgM, positivity with high IgG levels indicates secondary dengue and can be detected as early as 3 days post onset of illness till 15 days. A positive result (>22 Panbio™ units) in Panbio™ Dengue IgG Capture ELISA was considered as active secondary infection ( Santhosh Kumar et al., 2021 ). The viral load in the daily collected serum samples was estimated using real-time RT-PCR targeting the untranslated region (UTR) of DENV, as described previously ( Gurukumar et al., 2009 ).…”

mentioning

confidence: 99%

Temporal cytokine storm dynamics in dengue infection predicts severity

Bhatt,

Varma,

Sood

et al. 2024

Virus Research

View full text Add to dashboard Cite

Attrition in serum anti-DENV antibodies correlates with high anti-SARS-CoV-2 IgG levels and low DENV positivity in mosquito vectors—Findings from a state-wide cluster-randomized community-based study in Tamil Nadu, India

Selvavinayagam,

Sankar,

Yong

et al. 2024

PLOS Glob Public Health

View full text Add to dashboard Cite

The decline in dengue incidence and/or prevalence during the COVID-19 pandemic (2020–22) appears to be attributed to reduced treatment-seeking rates, under-reporting, misdiagnosis, disrupted health services and reduced exposure to mosquito vectors due to prevailing lockdowns. There is limited scientific data on dengue virus (DENV) disease during the COVID-19 pandemic. Here, we conducted a community-based, cross-sectional, cluster-randomized survey to assess anti-DENV and anti-SARS-CoV-2 seroprevalence, and also estimated the spatial distribution of DENV-positive aedine mosquito vectors during the COVID-19 pandemic across all the 38 districts of Tamil Nadu, India. Using real-time PCR, the prevalence of DENV in mosquito pools during 2021 was analyzed and compared with the previous and following years of vector surveillance, and correlated with anti-DENV IgM and IgG levels in the population. Results implicate that both anti-DENV IgM and IgG seroprevalence and DENV positivity in mosquito pools were reduced across all the districts. A total of 13464 mosquito pools and 5577 human serum samples from 186 clusters were collected. Of these, 3.76% of the mosquito pools were positive for DENV. In the human sera, 4.12% were positive for anti-DENV IgM and 6.4% for anti-DENV IgG. While the anti-SARS-CoV-2 levels significantly correlated with overall DENV seropositivity, COVID-19 vaccination status significantly correlated with anti-DENV IgM levels. The study indicates a profound impact of anti-SARS-CoV-2 levels on DENV-positive mosquito pools and seropositivity. Continuous monitoring of anti-DENV antibody levels, especially with the evolving variants of SARS-CoV-2 and the surge in COVID-19 cases will shed light on the distribution, transmission and therapeutic attributes of DENV infection.

show abstract

Seroprevalence of Dengue Infection Using IgG Capture ELISA in India, 2017–2018

Cited by 3 publications

References 7 publications

Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study

Comparing the performance of dengue virus IgG and IgG-capture enzyme-linked immunosorbent assays in seroprevalence study

Temporal cytokine storm dynamics in dengue infection predicts severity

Attrition in serum anti-DENV antibodies correlates with high anti-SARS-CoV-2 IgG levels and low DENV positivity in mosquito vectors—Findings from a state-wide cluster-randomized community-based study in Tamil Nadu, India

Contact Info

Product

Resources

About